{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=22",
    "query": {
      "intervention": "gemcitabine",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1628,
    "total_pages": 163,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T14:30:35.951Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05325281",
      "title": "CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreas Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "CPI-613® (Dose level -1.0 250 mg/m^2)",
          "type": "DRUG"
        },
        {
          "name": "CPI-613® (Dose level 1.0 500 mg/m^2)",
          "type": "DRUG"
        },
        {
          "name": "CPI-613® (Dose level 2.0 1,000 mg/m^2)",
          "type": "DRUG"
        },
        {
          "name": "CPI-613® (Dose level 3.0 1,500 mg/m^2)",
          "type": "DRUG"
        },
        {
          "name": "CPI-613® Maximum Tolerated Dose (MTD)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Intensity-modulated Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-10-31",
      "completion_date": "2025-07-08",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05325281"
    },
    {
      "nct_id": "NCT00191152",
      "title": "A Phase III Trial For Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasms",
        "Cancer of the Breast"
      ],
      "interventions": [
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 475,
      "start_date": "2002-02",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2009-12-24",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 47,
      "location_summary": "Glendale, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 44 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00191152"
    },
    {
      "nct_id": "NCT07322263",
      "title": "Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Non-Muscle Invasive Bladder Cancer (NMIBC)",
        "Urothelial Carcinoma",
        "Carcinoma in Situ (CIS)",
        "High-Grade Papillary Bladder Tumors",
        "BCG-Unresponsive Bladder Cancer",
        "Ta Stage Bladder Cancer",
        "T1 Stage Bladder Cancer",
        "BCG-Refractory Bladder Cancer",
        "High-Risk NMIBC",
        "Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)"
      ],
      "interventions": [
        {
          "name": "Intravesical Gemcitabine and Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael A. O'Donnell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 174,
      "start_date": "2026-04-10",
      "completion_date": "2033-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07322263"
    },
    {
      "nct_id": "NCT00955721",
      "title": "A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma",
        "Biliary Tract Cancer",
        "Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2009-08",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2018-01-03",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955721"
    },
    {
      "nct_id": "NCT00005926",
      "title": "Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Herceptin",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 50,
      "start_date": "2000-06",
      "completion_date": "2000-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005926"
    },
    {
      "nct_id": "NCT03257033",
      "title": "Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "RenovoCath",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "RenovoRx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2018-03-12",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 26,
      "location_summary": "Loma Linda, California • Sacramento, California • Washington D.C., District of Columbia + 23 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03257033"
    },
    {
      "nct_id": "NCT03579771",
      "title": "Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Resectable Cholangiocarcinoma",
        "Stage IB Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage II Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-09-26",
      "completion_date": "2023-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Rochester, Minnesota • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03579771"
    },
    {
      "nct_id": "NCT02722538",
      "title": "Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taris Biomedical LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2016-05-31",
      "completion_date": "2019-05-02",
      "has_results": false,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722538"
    },
    {
      "nct_id": "NCT01555489",
      "title": "Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Ascorbic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2011-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01555489"
    },
    {
      "nct_id": "NCT01936974",
      "title": "(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Carcinoma",
        "Fallopian Tube Carcinoma",
        "Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Western Regional Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2013-09",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-02-20",
      "last_synced_at": "2026-10-25T14:30:35.951Z",
      "location_count": 1,
      "location_summary": "Goodyear, Arizona",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01936974"
    }
  ]
}